# Lyudmila Bazhenova

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/lyudmila-bazhenova/

## Facts

| Field | Value |
| --- | --- |
| Citations | 17,677 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 55 |
| i10-index | 117 |
| Last Known Institution | University of San Diego |
| OpenAlex ID | https://openalex.org/A5036466135 |
| ORCID iD | 0000-0001-8764-4359 |
| Works | 430 |

## Researcher papers

- [Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers](https://scholariq.org/papers/tumor-mutational-burden-as-an-independent-predictor-of-response-to-immunotherapy/)
- [Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials](https://scholariq.org/papers/entrectinib-in-patients-with-advanced-or-metastatic-ntrk-fusion-positive-solid/)
- [Adagrasib in Non–Small-Cell Lung Cancer Harboring a <i> KRAS <sup>G12C</sup> </i> Mutation](https://scholariq.org/papers/adagrasib-in-non-small-cell-lung-cancer-harboring-a-i-kras-sup-g12c-sup-i/)
- [Trastuzumab Deruxtecan in <i>HER2</i> -Mutant Non–Small-Cell Lung Cancer](https://scholariq.org/papers/trastuzumab-deruxtecan-in-i-her2-i-mutant-non-small-cell-lung-cancer/)
- [Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/efficacy-of-selpercatinib-in-i-ret-i-fusion-positive-non-small-cell-lung-cancer/)
- [NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016](https://scholariq.org/papers/nccn-guidelines-insights-non-small-cell-lung-cancer-version-4-2016/)
- [Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study](https://scholariq.org/papers/osimertinib-for-pretreated-egfr-thr790met-positive-advanced-non-small-cell-lung/)
- [Non–Small Cell Lung Cancer, Version 6.2015](https://scholariq.org/papers/non-small-cell-lung-cancer-version-6-2015/)
- [Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial](https://scholariq.org/papers/activity-and-safety-of-brigatinib-in-alk-rearranged-non-small-cell-lung-cancer/)
- [Analysis of <i>NTRK</i> Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics](https://scholariq.org/papers/analysis-of-i-ntrk-i-alterations-in-pan-cancer-adult-and-pediatric-malignancies/)
- [Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial](https://scholariq.org/papers/safety-efficacy-and-pharmacokinetics-of-almonertinib-hs-10296-in-pretreated/)
- [Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy](https://scholariq.org/papers/clinicopathologic-and-molecular-characteristics-of-egfr-mutant-lung/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

## Researcher university

- [University of San Diego](https://scholariq.org/institutions/university-of-san-diego/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.